Critical Review

You have full text access to this OnlineOpen article

Asthma management: Reinventing the wheel in sickle cell disease†

  1. Claudia R. Morris*

Article first published online: 31 DEC 2008

DOI: 10.1002/ajh.21359

Issue

American Journal of Hematology

American Journal of Hematology

Volume 84, Issue 4, pages 234–241, April 2009

Additional Information

How to Cite

Morris, C. R. (2009), Asthma management: Reinventing the wheel in sickle cell disease. Am. J. Hematol., 84: 234–241. doi: 10.1002/ajh.21359

Author Information

  1. Department of Emergency Medicine, Children's Hospital and Research Center Oakland, Oakland, California

*Department of Emergency Medicine, Children's Hospital and Research Center Oakland, 747 52nd Street, Oakland, CA 94609

  1. †

    Conflict of Interest: Nothing to report.

Publication History

  1. Issue published online: 25 MAR 2009
  2. Article first published online: 31 DEC 2008
  3. Accepted manuscript online: 31 DEC 2008 12:00AM EST
  4. Manuscript Accepted: 22 DEC 2008
  5. Manuscript Revised: 21 DEC 2008
  6. Manuscript Received: 29 OCT 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (242K)

References

  • 1
    Larsen GL. Asthma in children. N Engl J Med 1992; 326: 1540–1545.
  • 2
    Elias JA,Zhu Z,Chupp G, et al. Airway remodeling in asthma. J Clin Invest 1999; 104: 1001–1006.
  • 3
    Elias JA,Lee CG,Zheng T, et al. New insights into the pathogenesis of asthma. J Clin Invest 2003; 111: 291–297.
  • 4
    Busse WW,Lemanske RFJr. Asthma. N Engl J Med 2001; 344: 350–362.
  • 5
    Koumbourlis AC,Zar HJ,Hurlet-Jensen A, et al. Prevalence and reversibility of lower airway obstruction in children with sickle cell disease. J Pediatr 2001; 138: 188–192.
  • 6
    Morris CR,Kuypers FA,Lavrisha L, et al. Elevated arginase activity and limited arginine bioavailability: A common feature of asthma and sickle cell disease. Blood 2003; 102: 764a (abstr 2819).
  • 7
    Boyd JH,Moinuddin A,Strunk RC, et al. Asthma and acute chest in sickle-cell disease. Pediatr Pulmonol 2004; 38: 229–232.
    Direct Link:
  • 8
    Bryant R. Asthma in the pediatric sickle cell patient with acute chest syndrome. J Pediatr Health Care 2005; 19: 157–162.
  • 9
    Knight-Madden JM,Forrester TS,Lewis NA, et al. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax 2005; 60: 206–210.
  • 10
    Nordness ME,Lynn J,Zacharisen MC, et al. Asthma is a risk factor for acute chest syndrome and cerebral vascular accidents in children with sickle cell disease. Clin Mol Allergy 2005; 3: 2.
  • 11
    Boyd JH,Macklin EA,Strunk RC, et al. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood 2006; 108: 2923–2927.
  • 12
    Sylvester KP,Patey RA,Broughton S, et al. Temporal relationship of asthma to acute chest syndrome in sickle cell disease. Pediatr Pulmonol 2007; 42: 103–106.
    Direct Link:
  • 13
    Boyd JH,Macklin EA,Strunk RC, et al. Asthma is associated with increased mortality in patients with sickle cell anemia. Haematologica 2007; 92: 1115–1118.
  • 14
    Hagar RW,Michlitsch JG,Gardner J, et al. Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br J Haematol 2008; 140: 104–112.
  • 15
    Morris CR. Mechanisms of vascular dysfunction in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program 2008; 2008: 177–185
  • 16
    Duckworth L,Hsu L,Feng H, et al. Physician-diagnosed asthma and acute chest syndrome: Associations with NOS Polymorphisms. Pediatr Pulmonol 2007; 42: 332–338.
    Direct Link:
  • 17
    Morris CR,Gardner J,Wen A, et al. Abnormal pulmonary function in adults and children with sickle cell disease. Blood 2005; 106: 652a (abstr 2319).
  • 18
    Bernaudin F,Strunk RC,Kamdem A, et al. Asthma is associated with acute chest syndrome, but not with an increased rate of hospitalization for pain among children in France with sickle cell anemia: A retrospective cohort study. Haematologica 2008; 93: 1917–1918.
  • 19
    Nandedkar SD,Feroah TR,Hutchins W, et al. Histopathology of experimentally induced asthma in a murine model of sickle cell disease. Blood 2008; 112: 2529–2538.
  • 20
    New NHLBI guidelines for the diagnosis and management of asthma. National Heart, Lung and Blood Institute. Lippincott Health Promot Lett 1997; 2: 1,8–9.
  • 21
    Denlinger LC,Sorkness CA,Chinchilli VM, et al. Guideline-defining asthma clinical trials of the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research and Education Network. J Allergy Clin Immunol 2007; 119: 3–11; quiz 12-13.
  • 22
    Rastogi D,Shetty A,Neugebauer R, et al. National Heart, Lung, and Blood Institute guidelines and asthma management practices among inner-city pediatric primary care providers. Chest 2006; 129: 619–623.
  • 23
    Moore WC. Update in asthma 2007. Am J Respir Crit Care Med 2008; 177: 1068–1073.
  • 24
    National Asthma Education and Prevention Program Expert Panel Report 3. Guidelines for the diagnosis and management of asthma. Bethesda: National Heart, Lung and Blood Institutes, National Institutes of Health; 2007.
  • 25
    Meng YY,Babey SH,Malcolm E, et al. Asthma in California: Findings from the 2001 California Health Interview Survey. Los Angeles: UCLA Center for Health Policy Research; 2003.
  • 26
    Yeatts KB,Shy CM. Prevalence and consequences of asthma and wheezing in African-American and White adolescents. J Adolesc Health 2001; 29: 314–319.
  • 27
    Webber MP,Carpiniello KE,Oruwariye T, et al. Prevalence of asthma and asthma-like symptoms in inner-city elementary schoolchildren. Pediatr Pulmonol 2002; 34: 105–111.
    Direct Link:
  • 28
    Gladwin M,Sachdev V,Jison M, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350: 22–31.
  • 29
    Ataga KI,Sood N,De Gent G, et al. Pulmonary hypertension in sickle cell disease. Am J Med 2004; 117: 665–669.
  • 30
    Klings ES. Pulmonary hypertension of sickle cell disease: More than just another lung disease. Am J Hematol 2008; 83: 4–5.
    Direct Link:
  • 31
    De Castro LM,Jonassaint JC,Graham FL, et al. Pulmonary hypertension associated with sickle cell disease: Clinical and laboratory endpoints and disease outcomes. Am J Hematol 2008; 83: 19–25.
    Direct Link:
  • 32
    Morris CR,Gardner J,Hagar W, et al. Pulmonary hypertension in sickle cell disease: A common complication for both adults and children. The 27th Annual Meeting of the National Sickle Cell Program. Los Angeles, CA; 2003.
  • 33
    Kato GJ,Onyekwere OC,Gladwin MT. Pulmonary hypertension in sickle cell disease: Relevance to children. Pediatr Hematol Oncol 2007; 24: 159–170.
  • 34
    Pashankar FD,Carbonella J,Bazzy-Asaad A, et al. Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics 2008; 121: 777–782.
  • 35
    Onyekwere OC,Campbell A,Teshome M, et al. Pulmonary hypertension in children and adolescents with sickle cell disease. Pediatr Cardiol 2008; 29: 309–312.
  • 36
    Caboot JB,Allen JL. Pulmonary complications of sickle cell disease in children. Curr Opin Pediatr 2008; 20: 279–287.
  • 37
    Taylor JGt,Ackah D,Cobb C, et al. Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol 2008; 83: 6–14.
    Direct Link:
  • 38
    Sofowora EO. Bronchial asthma in the tropics. A study of 250 Nigerian patients. East Afr Med J 1970; 47: 434–439.
  • 39
    Caplin I,Haynes JT,Lloyd F. Incidence and significance of sickle cell trait in asthma. Ann Allergy 1972; 30: 623–626.
  • 40
    Morris CR,Kuypers FA,Larkin S, et al. Patterns of arginine and nitric oxide in sickle cell disease patients with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000; 22: 515–520.
  • 41
    Morris CR,Kuypers FA,Larkin S, et al. Arginine therapy: A novel strategy to increase nitric oxide production in sickle cell disease. Brit J Haematol 2000; 111: 498–500.
  • 42
    Morris CR,Morris SMJr,Hagar W, et al. Arginine therapy: A new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003; 168: 63–69.
  • 43
    Morris CR,Poljakovic M,Lavisha L, et al. Decreased arginine bioavailability and increased arginase activity in asthma. Am J Respir Crit Care Med 2004; 170: 148–153.
  • 44
    Morris CR. New strategies for the treatment of pulmonary hypertension in sickle cell disease: The rationale for arginine therapy. Treat Respir Med 2006; 5: 31–45.
  • 45
    Morris CR. Hemolysis-associated pulmonary hypertension in sickle cell disease: Global disruption of the arginine-nitric oxide pathway. Curr Hypertens Rev 2007; 3: 223–230.
  • 46
    Enwonwu CO. Increased metabolic demand for arginine in sickle cell anaemia. Med Sci Res 1989; 17: 997–998.
  • 47
    Schnog JB,Jager EH,van der Dijs FP, et al. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann Hematol 2004; 83: 371–375.
  • 48
    Dasgupta T,Hebbel RP,Kaul DK. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med 2006; 41: 1771–1780.
  • 49
    Landburg PP,Teerlink T,Muskiet FA, et al. Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisis. Am J Hematol 2008; 83: 577–579.
    Direct Link:
  • 50
    Kaul DK,Zhang X,Dasgupta T, et al. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis and oxidative stress. Am J Physiol Heart Circ Physiol 2008; 295: H39–H47.
  • 51
    Schnog JB,Teerlink T,van der Dijs FP, et al. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann Hematol 2005; 84: 282–286.
  • 52
    Hsu LL,Champion HC,Campbell-Lee SA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 2007; 109: 3088–3098.
  • 53
    Wood KC,Hebbel RP,Lefer DJ, et al. Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease-induced microvascular dysfunction. Free Radic Biol Med 2006; 40: 1443–1453.
  • 54
    Morris CR,Gladwin MT,Kato G. Nitric oxide and arginine dysregulation: A novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med 2008; 8: 620–632.
  • 55
    Morris CR,Kato GJ,Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA 2005; 294: 81–90.
  • 56
    Zimmermann N,King NE,Laporte J, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest 2003; 111: 1863–1874.
  • 57
    Meurs H,Maarsingh H,Zaagsma J. Arginase and asthma: Novel insights into nitric oxide homeostatis and airway hyperresponsiveness. Trends Pharmacol Sci 2003; 24: 450–455.
  • 58
    King NE,Rothenberg ME,Zimmermann N. Arginine in asthma and lung inflammation. J Nutr 2004; 134: 2830S–2836S; discussion 2853S.
  • 59
    Maarsingh H,Leusink J,Bos IS, et al. Arginase strongly impairs neuronal nitric oxide-mediated airway smooth muscle relaxation in allergic asthma. Respir Res 2006; 7: 6.
  • 60
    Li H,Romieu I,Sienra-Monge JJ, et al. Genetic polymorphisms in arginase I and II and childhood asthma and atopy. J Allergy Clin Immunol 2006; 117: 119–126.
  • 61
    Lara A,Khatri SB,Wang Z, et al. Alterations of the arginine metabolome in asthma. Am J Respir Crit Care Med 2008; 178: 673–681.
  • 62
    Litonjua AA,Lasky-Su J,Schneiter K, et al. ARG1 is a novel bronchodilator response gene: Screening and replication in four asthma cohorts. Am J Respir Crit Care Med 2008; 178: 688–694.
  • 63
    Maarsingh H,Zuidhof AB,Bos IS, et al. Arginase inhibition protects against allergen-induced airway obstruction, hyperresponsiveness, and inflammation. Am J Respir Crit Care Med 2008; 178: 565–573.
  • 64
    Vosatka R,Kashyap S,Trifiletti R. Arginine deficiency accompanies persistent pulmonary hypertension of the newborn. Biol Neonate 1994; 66: 65–70.
  • 65
    Morris CR,Teehankee C,Kato G, et al. Decreased arginine bioavailability contributes to the pathogenesis of pulmonary artery hypertension. American College of Cardiology Annual Meeting, Orlando, Florida; 2005.
  • 66
    Morris CR,Kuypers FA,Kato GJ, et al. Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci 2005; 1054: 481–485.
    Direct Link:
  • 67
    Morris CR,Vichinsky E,Singer ST. Pulmonary hypertension in thalassemia: Association with hemolysis, arginine metabolism dysregulation and a hypercoaguable state. Adv Pulm Hypertens 2007; 5: 31–38.
  • 68
    Xu W,Kaneko TF,Zheng S, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004; 18: 1746–1748.
  • 69
    Wu G,Morris SMJr. Arginine metabolism: Nitric oxide and beyond. Biochem J 1998; 336: 1–17.
  • 70
    Rother RP,Bell L,Hillmen P, et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 2005; 293: 1653–1662.
  • 71
    Zharikov S,Block E. Association of L-arginine transporters with fodrin: Implications for hypoxic inhibition of arginine uptake. Am J Physiol Lung Cell Mol Physiol 2000; 278: L111–L117.
  • 72
    Graf P,Forstermann U,Closs E. The transport activity of the human cationic amino acid transporter hCAT-1 is downregulated by activation of protein kinase C. Br J Pharmacol 2001; 132: 1193–1200.
    Direct Link:
  • 73
    Reiter C,Wang X,Tanus-Santos J, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nat Med 2002; 8: 1383–1389.
  • 74
    Dias-Da-Motta P,Arruda V,Muscara M, et al. The release of nitric oxide and superoxide anion by neutrophils and mononuclear cells from patients with sickle cell anaemia. Brit J Haematol 1996; 93: 333–340.
    Direct Link:
  • 75
    Aslan M,Ryan TM,Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 2001; 98: 15215–15220.
  • 76
    Aslan M,Freeman BA. Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease–mechanisms and consequences. Cell Mol Biol (Noisy-le-grand) 2004; 50: 95–105.
  • 77
    Das SK,Nair RC. Superoxide dismutase, glutathione peroxidase, catalase and lipid peroxidation of normal and sickled erythrocytes. Br J Haematol 1980; 44: 87–92.
    Direct Link:
  • 78
    Schacter L,Warth JA,Gordon EM, et al. Altered amount and activity of superoxide dismutase in sickle cell disease. FASEB J 1988; 2: 237–243.
  • 79
    Xia Y,Dawson V,Dawson T, et al. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 1996; 93: 6770–6774.
  • 80
    Kato GJ,Gladwin MT,Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007; 21: 37–47.
  • 81
    Schnog JJ,Jager EH,van der Dijs FP, et al. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann Hematol 2004; 83: 371–375.
  • 82
    Meurs H,Maarsingh H,Zaagsma J. Arginase and asthma: Novel insights into nitric oxide homeostasis and airway hyperresponsiveness. Trends Pharmacol Sci 2003; 24: 450–455.
  • 83
    Zimmermann N,King NE,Laporte J, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest 2003; 111: 1863–1874.
  • 84
    Ricciardolo FL,Zaagsma J,Meurs H. The therapeutic potential of drugs targeting the arginase pathway in asthma. Expert Opin Invest Drugs 2005; 14: 1221–1231.
  • 85
    Morris CR,Poljakovic M,Lavrisha L, et al. Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med 2004; 170: 148–153.
  • 86
    Boer J,Duyvendak M,Schuurman FE, et al. Role of L-arginine in the deficiency of nitric oxide and airway hyperreactivity after the allergen-induced early asthmatic reaction in guinea-pigs. Br J Pharmacol 1999; 128: 1114–1120.
    Direct Link:
  • 87
    Langle F,Roth E,Steininger R, et al. Arginase release following liver reperfusion. Evidence of hemodynamic action of arginase infusions. Transplantation 1995; 59: 1542–1549.
  • 88
    Sullivan K,Kissoon N,Duckworth L, et al. Low exhaled nitric oxide and a polymorphism in the NOS I gene is associated with acute chest syndrome. Am J Respir Crit Care Med 2001; 164: 2186–2190.
  • 89
    Onyekwere OC,Campbell A,Teshome M, et al. Pulmonary hypertension in children and adolescents with sickle cell disease. Pediatr Cardiol 2008; 29: 309–12.
  • 90
    Phillips KL,An P,Boyd JH, et al. Major gene effect and additive familial pattern of inheritance of asthma exist among families of probands with sickle cell anemia and asthma. Am J Hum Biol 2008; 20: 149–153.
    Direct Link:
  • 91
    de Benedictis FM,Canny GJ,MacLusky IB, et al. Comparison of airway reactivity induced by cold air and metacholine challenges in asthmatic children. Pediatr Pulmonol 1995; 19: 326–329.
    Direct Link:
  • 92
    Vendramini EC,Vianna EO,De Lucena Angulo I, et al. Lung function and airway hyperresponsiveness in adult patients with sickle cell disease. Am J Med Sci 2006; 332: 68–72.
  • 93
    Ozbek OY,Malbora B,Sen N, et al. Airway hyperreactivity detected by methacholine challenge in children with sickle cell disease. Pediatr Pulmonol 2007; 42: 1187–1192.
    Direct Link:
  • 94
    Strunk RC,Brown MS,Boyd JH, et al. Methacholine challenge in children with sickle cell disease: A case series. Pediatr Pulmonol 2008; 43: 924–929.
    Direct Link:
  • 95
    Koumbourlis AC,Lee DJ,Lee A. Longitudinal changes in lung function and somatic growth in children with sickle cell disease. Pediatr Pulmonol 2007; 42: 483–488.
    Direct Link:
  • 96
    Maclean JE,Atenafu E,Kirby-Allen M, et al. Longitudinal decline in lung volume in a population of children with sickle cell disease. Am J Respir Crit Care Med 2008; 178: 1005–1009.
  • 97
    Field JJ,Glassberg J,Gilmore A, et al. Longitudinal analysis of pulmonary function in adults with sickle cell disease. Am J Hematol 2008; 32: 85–96.
  • 98
    Klings ES,Wyszynski DF,Nolan VG, et al. Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med 2006; 173: 1264–1269.
  • 99
    Gladwin MT,Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359: 2254–2265.
  • 100
    Song TW,Kim KW,Kim ES, et al. Correlation between spirometry and impulse oscillometry in children with asthma. Acta Paediatr 2008; 97: 51–54.
    Direct Link:
  • 101
    Field JJ,Macklin EA,Yan Y, et al. Sibling history of asthma is a risk factor for pain in children with sickle cell anemia. Am J Hematol 2008; 83: 855–857.
    Direct Link:
  • 102
    Zennadi R,Moeller BJ,Whalen EJ, et al. Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood 2007; 110: 2708–2717.
  • 103
    Zennadi R,Hines PC,De Castro LM, et al. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. Blood 2004; 104: 3774–3781.
  • 104
    Zennadi R,Chien A,Xu K, et al. Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood 2008; 112: 3474–3483.
  • 105
    Telen MJ. Role of adhesion molecules and vascular endothelium in the pathogenesis of sickle cell disease. Hematology Am Soc Hematol Educ Program 2007; 2007: 84–90.
  • 106
    Hines PC,Zen Q,Burney SN, et al. Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. Blood 2003; 101: 3281–3287.
  • 107
    Eyler CE,Jackson T,Elliott LE, et al. β(2)-Adrenergic receptor and adenylate cyclase gene polymorphisms affect sickle red cell adhesion. Br J Haematol 2008; 141: 105–108.
    Direct Link:
  • 108
    Mueller BU,Martin KJ,Dreyer W, et al. Prolonged QT interval in pediatric sickle cell disease. Pediatr Blood Cancer 2006; 47: 831–833.
    Direct Link:
  • 109
    Boga C,Kozanoglu I,Yeral M, et al. Assessment of corrected QT interval in sickle-cell disease patients who undergo erythroapheresis. Transfus Med 2007; 17: 466–472.
  • 110
    Akgul F,Seyfeli E,Melek I, et al. Increased QT dispersion in sickle cell disease: Effect of pulmonary hypertension. Acta Haematol 2007; 118: 1–6.
  • 111
    Thottathil P,Acharya J,Moss AJ, et al. Risk of cardiac events in patients with asthma and long-QT syndrome treated with β(2) agonists. Am J Cardiol 2008; 102: 871–874.
  • 112
    Liesner RJ,Vandenberghe FA. Sudden death in sickle cell disease. J R Soc Med 1993; 86: 484–485.
  • 113
    Romero Mestre JC,Hernandez A,Agramonte O, et al. Cardiovascular autonomic dysfunction in sickle cell anemia: A possible risk factor for sudden death? Clin Auton Res 1997; 7: 121–125.
  • 114
    Manci EA,Culberson DE,Yang YM, et al. Causes of death in sickle cell disease: An autopsy study. Br J Haematol 2003; 123: 359–365.
    Direct Link:
  • 115
    Darbari DS,Kple-Faget P,Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006; 81: 858–863.
    Direct Link:
  • 116
    Graham JK,Mosunjac M,Hanzlick RL, et al. Sickle cell lung disease and sudden death: A retrospective/prospective study of 21 autopsy cases and literature review. Am J Forensic Med Pathol 2007; 28: 168–172.
  • 117
    Gladman DD,Bombardier C. Sickle cell crisis following intraarticular steroid therapy for rheumatoid arthritis. Arthritis Rheum 1987; 30: 1065–1068.
    Direct Link:
  • 118
    Strouse JJ,Takemoto CM,Keefer JR, et al. Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatr Blood Cancer 2008; 50: 1006–1012.
    Direct Link:
  • 119
    Darbari DS,Castro O,Taylor JGT, et al. Severe vaso-occlusive episodes associated with use of systemic corticosteroids in patients with sickle cell disease. J Natl Med Assoc 2008; 100: 948–951.
  • 120
    Griffin TC,McIntire D,Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 1994; 330: 733–737.
  • 121
    Robinson B. Reversal of sickle-cell crisis by dexamethasone. Lancet 1979; 1: 1088.
  • 122
    Bernini JC,Rogers ZR,Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998; 92: 3082–3089.
  • 123
    Isakoff MS,Lillo JA,Hagstrom JN. A single-institution experience with treatment of severe acute chest syndrome: Lack of rebound pain with dexamethasone plus transfusion therapy. J Pediatr Hematol Oncol 2008; 30: 322–325.
  • 124
    Embury SH,Garcia JF,Mohandas N, et al. Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia. N Engl J Med 1984; 311: 291–295.
  • 125
    Machado RF,Kyle Mack A,Martyr S, et al. Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. Br J Haematol 2007; 136: 319–325.
    Direct Link:
  • 126
    Morris C,Vichinsky E,Styles L. Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: Is it accurate enough? Ann Emerg Med 1999; 34: 64–69.
  • 127
    Ibe BO,Kurantsin-Mills J,Raj JU, et al. Plasma and urinary leukotrienes in sickle cell disease: Possible role in the inflammatory process [see comments]. Eur J Clin Invest 1994; 24: 57–64.
    Direct Link:
  • 128
    Jennings JE,Ramkumar T,Mao J, et al. Elevated urinary leukotriene E4 levels are associated with hospitalization for pain in children with sickle cell disease. Am J Hematol 2008; 83: 640–643.
    Direct Link:
  • 129
    Johnson K,Stastny JF,Rucknagel DL. Fat embolism syndrome associated with asthma and sickle cell-β+ -thalassemia. Am JHematol 1994; 46: 354–357.
    Direct Link:
  • 130
    Glassberg J,Spivey JF,Strunk R, et al. Painful episodes in children with sickle cell disease and asthma are temporally associated with respiratory symptoms. J Pediatr Hematol Oncol 2006; 28: 481–485.
  • 131
    Neumayr L,Morris CR,Wen A, et al. Reversible loss of pulmonary function induced by acute chest syndrome in sickle cell disease. Blood 2005; 106: 96a [abstr 315].
  • 132
    Vichinsky E,Neumayr L,Earles A, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National acute chest syndrome study group. N Engl J Med 2000; 342: 1855–1865.
  • 133
    Jani AL,Hamilos DL. Current thinking on the relationship between rhinosinusitis and asthma. J Asthma 2005; 42: 1–7.
  • 134
    Teodorescu M,Consens FB,Bria WF, et al. Predictors of habitual snoring and obstructive sleep apnea risk in patients with asthma. Chest, 2008. Oct 10 [Epub ahead of print].
  • 135
    Debley JS,Carter ER,Redding GJ. Prevalence and impact of gastroesophageal reflux in adolescents with asthma: A population-based study. Pediatr Pulmonol 2006; 41: 475–481.
    Direct Link:
Get PDF (242K)